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Abstract  
Introduction 
This work aimed to ascertain future pharmacists’ use of, and attitudes towards, cognitive 
enhancers (CEs).  
Methods 
Following ethical approval, all first and final year pharmacy students at Queen’s University 
Belfast (QUB) were invited to complete a pre-piloted, non-identifiable, paper-based 
questionnaire during a compulsory class. Descriptive statistics were undertaken; non-
parametric tests were used for comparisons with significance set at p<0.05 a priori. 
Results 
The response rates were 89.3% (Level 1) and 89.0% (Level 4) with 48.0% of respondents 
reporting they were CE users (largely caffeine). Additionally, 42.4% thought using 
pharmaceutical CEs for improving academic grades breached their Code of Conduct. Level 4 
students were more likely to associate OTC and POM CEs with side effects than Level 1 [OTC 
statement p=0.001 and POM statement p=0.016]. 
Discussion 
CE use among future pharmacists seems quite high; Level 1 students appear more naïve about 
safety concerns. Educational workshops could further explore ethical issues.  
 
Keywords 
cognitive enhancers, pharmacy students, questionnaire 
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Introduction (unidentified/blinded) 
Cognitive enhancers (also known as ‘smart drugs’, ‘study aids’ or ‘nootropics’) are used to 
improve cognitive function, particularly functions such as memory, alertness, creativity and 
motivation (Smith and Farah, 2011; Ragan et al., 2013). For the purposes of this study, 
cognitive enhancers (CEs) are substances which provide cognitive enhancement to an 
otherwise healthy individual who does not have cognitive impairment or a medical need (i.e. 
this work does not relate to cognitive enhancing medicines for treating cognitive impairment 
due to a medical condition such as dementia).  
 
Researchers have tried to classify CEs but their efforts have been pampered by the plethora of 
substances claiming to have cognitive enhancing properties (Nutt et al., 2007; Academy of 
Medical Sciences, 2008). Commonly recognised CEs are caffeine (found in numerous products 
including coffee and energy drinks), ephedrine and pseudoephedrine [over-the-counter (OTC) 
medicines found in cough and cold products], prescription-only medicines (POMs) such as 
methylphenidate indicated for attention deficit hyperactivity disorder (ADHD) (Ragan et al., 
2013; Linssen et al., 2014; Weyandt et al., 2016; Jain et al., 2017) and modafinil indicated for 
narcolepsy (Turner et al., 2004; Minzenberg and Carter, 2008; Ragan et al., 2013). Alcohol 
and illegal drugs such as cocaine may also be used for cognitive enhancement purposes (Franke 
et al., 2011). Much of the existing literature focusses on drugs with past or present medical 
uses i.e. caffeine, amphetamines, methylphenidate and modafinil, since their effects on 
cognitive function have been evaluated via randomised controlled trials (Arnold, 2000; Faraone 
et al., 2004; Turner et al., 2004; Minzenberg and Carter, 2008). 
 
CEs may be used within the university student population to enhance academic performance, 
such as meeting assignment deadlines and examination revision (Ragan et al., 2013). Typically, 
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as stress levels among university students increases, the use of CEs appears to increase too 
(Ragan et al., 2013).  In terms of the existing body of literature, results are difficult to decipher 
due to the variety of study designs, drugs investigated and definitions/categories employed. CE 
prevalence data largely relates to research conducted among US university students (see for 
example, Wilens et al., 2008; Smith and Farah, 2011) with fraternity and sorority members 
showing high rates of use (DeSantis et al., 2010). CE prevalence data in Europe is less 
comprehensive (studies include: Franke et al., 2011; Castaldi et al., 2012; Eickenhorst et al., 
2012; Maier et al., 2013; Singh et al., 2013; Ott and Biller-Andorno, 2014; Maier et al., 2015; 
Santacroce et al., 2016). Research on CE use in the United Kingdom (UK) university student 
population is sparse in comparison, although it has been mentioned in the media as a rapidly 
growing problem. A large-scale questionnaire study of cognitive enhancement (CE) use among 
students in the UK and Ireland (n=877 students) found lifetime prevalence of CE using 
modafinil or methylphenidate to be under 10%, with CE users more likely to be male (Singh 
et al., 2014).  
 
It would perhaps be expected that there would be substantial CE use among pharmacy students, 
given the high workload and academically challenging Master of Pharmacy (MPharm) degree 
programme. However, since such students are being trained to be experts in medicines, and 
future health care professionals bound by a professional code, perhaps safety and ethical 
concerns may limit CE use (particularly CEs such as amphetamines, methylphenidate and 
modafinil) among this population. Safety concerns for certain CEs include side-effects of the 
individual drugs and risks associated with online purchasing (British Medical Association, 
2015). Some pharmacy students may consider use of certain CEs for enhancing academic 
performance to be in opposition to aspects of the ‘Professional Standards’ (General 
Pharmaceutical Council, 2017) as it may suggest students are not taking appropriate 
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responsibility for their working practices or respecting others (General Pharmaceutical 
Council, 2017).  However, others may consider CE use to be ethical since it enhances 
performance and may be necessary when patient safety would otherwise be compromised (for 
example, when working long hours in a busy pharmacy). 
 
To the best of our knowledge, there has been limited work involving pharmacy students 
conducted in the UK and none specifically in Northern Ireland. This work adds to the field 
because it will provide data relating to future pharmacists in the UK. It is important to ascertain 
pharmacy students’ use and opinions on CEs, given that they are being trained to be experts in 
medicines. Furthermore, it was anticipated that the findings of this research would inform 
future teaching of the subject matter within the School and contribute to richer discussions 
around professionalism, ethics, and the safe and effective use of medicines (including personal 
use).  
 
Aims and objectives: 
The overall aim was to investigate Queen’s University Belfast (QUB) ‘Level 1’ and ‘Level 4’ 
pharmacy students’ use of, and views on, CEs. NB: ‘Level 1’ students, also known as ‘Year 1’ 
students, represent students who are enrolled on the first year of the MPharm degree 
programme. ‘Level 4’ students, also known as ‘Year 4’ students, represent students who are 
enrolled on the final year of the MPharm degree programme. 
The objectives were to: 
• investigate students’ personal use of CEs 
• obtain students’ views on safety and risks associated with CEs 
• establish students’ attitudes towards CE use for enhancing academic and professional 
performance 
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• determine whether certain factors (use, gender, and level of study) affected responses 
 
Method 
Ethical approval for this study was obtained from QUB School of Pharmacy Ethics Committee 
(Ref 024PMY2016).  
Study participants 
All currently enrolled Level 1 and Level 4 MPharm students at QUB were invited to participate 
in the study. The Level 1 cohort was selected to represent new university students. These 
students had not undertaken any written MPharm examinations at the time of data collection 
and none had previously completed a university degree. The Level 4 cohort was selected to 
represent students at the other end of the spectrum i.e. students who had completed at least 
three years of the MPharm degree course and were approaching completion and graduation.   
Data collection  
Data were collected by means of a paper-based, self-completed questionnaire.  
Questionnaire development 
The questionnaire was developed with reference to the wider literature (General 
Pharmaceutical Council, 2010; Smith and Farah, 2011; Costaldi et al., 2012; Eickenhorst et al., 
2012; Maier et al., 2013; Ragan et al., 2013; Singh et al., 2013; Ott and Biller-Andorno, 2014; 
Singh et al., 2014; Maier et al., 2015; Jensen et al., 2016). The questionnaire had three sections: 
Section A (4 questions in total, closed and open-response) related to personal use of CEs and 
included a question on use of modafinil and methylphenidate for their licensed indications since 
this may affect the likelihood of using certain substances for cognitive enhancement purposes 
(Ragan et al., 2013), Section B (2 closed questions with multiple statements measured using a 
5-point Likert scale from Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, 
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Strongly Disagree) focussed on attitudes towards CEs in relation to safety, risk and ethics and 
Section C (4 questions, largely closed) collected non-identifiable demographic information. 
Please note that at the time of conducting the study, MPharm students in the UK were bound 
by a professional code known as the ‘Code of Conduct’ (General Pharmaceutical Council, 
2010) which is referred to in several statements within the questionnaire. However, this ‘Code 
of Conduct’ has since been replaced by ‘Professional Standards’ (General Pharmaceutical 
Council, 2017).  
A cover sheet was prepared which outlined the purpose of the research and explained how the 
data would be used, included an explanation and examples of CEs and defined ‘off-label’ use, 
gave a predicted time required to complete the questionnaire and provided assurance that 
participation was voluntary. Reassurances about anonymity (and that no identifiable 
information was being collected) were also provided. This was particularly important for the 
questionnaire study, given the potentially sensitive nature of the topic. The questionnaire was 
piloted with ten pharmacist postgraduate students at QUB. As a result, an estimated completion 
time of 8 minutes was added to the cover sheet and minor amendments were made (Question 
3 was re-formatted so that it was not split across two pages). 
Questionnaire distribution  
This took place during in Semester 1 (December 2016). The researcher (Judith Rainey) went 
to scheduled Level 1 and Level 4 classes, having agreed this in advance with the lecturer in 
charge. She distributed the questionnaires, and directed the students to read the information on 
the cover sheet. Students were also asked to place completed questionnaires into a specific 
receptacle prior to vacating the venue. There was one distribution only (i.e. there was no follow-
up) which occurred when the majority of students were anticipated to be present in class, given 
attendance was compulsory.   
Maximising the response rate 
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We anticipated, based on previous work, that manually distributing paper-based questionnaires 
to students in a compulsory class would enhance the response rate over online distribution. 
Other ways to maximise the response rate included having a relatively short questionnaire with 
questions largely in a closed-question format (Dillman, 2008). 
Data analysis 
The responses from the completed questionnaires were coded and entered into a customised 
database developed on SPSS (Version 22) for statistical analysis in January 2017.  The analysis 
of the data largely took the form of descriptive statistics. Comparisons were done on male 
versus female responses as previous studies revealed gender differences in relation to usage of 
CEs (Dietz et al., 2013; Kudlow et al., 2013). We also investigated whether personal use of 
CEs influences responses, as this had been reported in other studies (Ott and Biller-Andorno, 
2014). Level 1 and Level 4 responses were compared; it was hypothesised that CE use would 
be greater among Level 4 than Level 1 students (Emanuel et al., 2013; Kudlow et al., 2013) 
since they have had more exposure to MPharm assessments and stressors associated with 
undertaking a university degree. Appropriate statistical tests (Mann-Whitney U-test and Chi-
squared) were conducted with significance set at p<0.05 a priori. Therefore, p values < 0.05 
are reported throughout the Results section. 
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Results 
The response rate was 89.6% (198/221); Level 4 had a response rate of 89.0% (97/109) and 
Level 1 had a response rate of 89.3% (100/112) but one respondent failed to provide details 
about their level of study. While the majority of respondents completed the questionnaire in its 
entirety (n=181), seventeen students left a few questions unanswered. The questionnaires from 
these seventeen students were included in the data analysis. The number of respondents who 
answered the question has been provided (in addition to the %). For example, stating “137/197 
‘strongly agreed’ or ‘agreed’…” means that 197 provided a response to the statement and of 
those, 137 ‘strongly agreed’ or ‘agreed’ with it.  In terms of statistical significance, only p 
values < 0.05 are reported throughout the Results section (rather than all p values for all parts). 
 
Demographic information (Section C of the questionnaire) 
Of the 198 respondents, 71 (35.9%) were males, 123 (62.1%) females, 3 (1.5%) ‘Preferred not 
to say’ and 1 (0.5%) did not select any of the three options. There were 97 (49.0%) Level 4 
students, 100 (50.5%) Level 1 students and 1 (0.5%) respondent who did not select either 
option.  The mean age of the Level 4 students was 22.8 years and the mean age of the Level 1 
students was 19.4 years. Moreover, 162 (81.8%) respondents received the majority of their 
education inside the European Union (EU) prior to coming to QUB, 28 (14.1%) received it 
outside the European Union (EU), and 8 respondents (4.0%) did not provide an answer.  
 
Personal use of CEs (Section A of the questionnaire) 
The proportion of students who reported using CEs [48.0% (95/198)] was similar to those 
reporting non-use [52.0% (103/198)].  
 Gender split - Males: 42.3% (30/71) were users and 57.7% (41/71) non-users; females: 
51.2% (63/123) were users and 48.8% (60/123) non-users  
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 Level split - Level 4: 49.5% (48/97) were users and 50.5% (49/97) non-users; Level 1: 
46.0% (46/100) were users and 54.0% (54/100) non-users 
None of the respondents reported currently taking (or ever taking) methylphenidate for 
attention-deficit hyperactivity disorder (ADHD) or modafinil for narcolepsy.  
 
Users were asked about what substances (up to a maximum of five) they used and the results 
are provided in Figure 1. 
Insert Figure 1 here please. 
When asked (via an open-response question) when they were likely to use CEs, the majority 
of users [72.6 % (69/95)] reported it was around exam time or when studying. Moreover, 30.5 
% (29/95) of users stated that they did so on a daily basis. Students were asked (again, via an 
open-response question) why they opted to use CEs. Reasons provided by users are outlined in 
Figure 2. 
Insert Figure 2 here please 
 
Reasons why non-users abstained from CEs were also investigated via an open-response 
question. The most commonly reported reason was that they considered use of CEs 
unnecessary [53.4 % (55/103)]. Other reasons were: lack of awareness of CEs [18.4% 
(19/103)], perceived lack of effectiveness [13.6% (14/103)], safety concerns [12.6% (13/103)], 
ethical concerns [8.7% (9/103)] and for other reasons [4.9% (5/103)] such as getting into 
trouble. 
 
Of the non-users, 9.7 % (10/103) stated that they would consider using CEs in the future, 62.1% 
(64/103) said they would not, and the remainder [28.2% (29/103)] were unsure. Females were 
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more likely to state that they would not use CEs in the future than males [70.0 % (42/60) 
females versus 53.7% (22/41) males; p=0.012]. 
 
Attitudes towards safety and risk (part of Section B of the questionnaire) 
Respondents were asked about their views on safety and risks associated with CE use (see 
Table I for responses).  
Insert Table I here please 
Level 4 students were more likely to associate OTC and POM CEs with side effects than Level 
1 [OTC statement p=0.001 and POM statement p=0.016]. 
Users were significantly more likely to “strongly disagree” or “disagree” that using CEs put 
students at risk of not developing key skills than non-users [34.0% (32/94) users versus 13.7% 
(14/102) non-users; p=0.003]. 
 
Attitudes towards CE use in the context of professionalism and ethics (part of Section B of 
the questionnaire) 
Respondents were asked about their views on ethics associated with CE use (see Table II for 
responses). It is worth noting the differences in opinion in relation to natural (i.e. non-
pharmaceutical) versus pharmaceutical CEs: 
 For the statements about CEs being ethical to use, 76.3% (151/198) of respondents 
‘Strongly Agreed’ or ‘Agreed’ in relation to natural CEs but this figure decreased to 
26.8% (53/198) for the OTC statement and 26.3% (52/198) for the POM statement.  
 Similarly, for the statements about CE use breaching the students’ Code of Conduct, 
only 13.1% (26/198) of respondents ‘Strongly agreed’ or ‘Agreed’ for natural CEs 
whereas 42.4% (84/198) ‘Strongly Agreed’ or ‘Agreed’ in relation to pharmaceutical 
CEs.  
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 Finally, for the statements about CE use breaching the pharmacist’s code of ethics, only 
15.2% (30/198) ‘Strongly agreed’ or ‘Agreed’ for natural CEs whereas 44.9% (89/198) 
‘Strongly Agreed’ or ‘Agreed’ in relation to pharmaceutical CEs. 
 
Insert Table II here please 
 
Level 4 students, in comparison to Level 1 students, were more likely to consider using natural 
substances as CEs was ethical [85.6% (83/97) Level 4 versus 67.0% (67/100) Level 1; 
p=0.022].  Furthermore, they were less likely to think that using natural substances to improve 
patient safety would breach the pharmacist’s ethical code [64.9% (63/97) Level 4 versus 46.0% 
(46/100) Level 1; p=0.011]. However, the reverse was seen with OTC medicines and POMs: 
Level 1 students were more likely to consider OTC CE use was ethical compared with Level 4 
students [34.0% (34/100) Level 1 versus 18.6 % (18/97) Level 4; p<0.001]. Similarly, Level 1 
students were more likely to consider that POM CE use was ethical [33.0% (33/100) Level 1 
versus 18.6% (18/97) Level 4; p=0.044)].   
 
CE users, compared with non-users, were more likely to be in disagreement that using natural 
substances as CEs to improve academic grades was a breach of the Code of Conduct [83.2% 
(79/95) users versus 45.6% (47/103) non-users; p<0.001]. CE users were more likely to be in 
disagreement that using natural CEs to potentially enhance patient safety in practice (for 
example, to improve concentration during long hours) breached the pharmacist’s ethical code 
[66.3% (63/95) users versus 44.7% (46/103) non-users; p=0.006]. Interestingly, there were no 
significant differences between user and non-user responses about the ethics of using OTC and 
POM CEs for these reasons (i.e. it was only in relation to natural CEs). 
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Females, in comparison to males, were more likely to consider that pharmaceutical CE use in 
academia was similar to doping in sports [48.8% (60/123) females versus 35.2% (25/71) males; 
p=0.037]. Males were more likely to “strongly agree” or “agree” with the statement “Mankind 
has always used substances to enhance performance; pharmaceutical CEs are just the most 
recent form of this phenomenon,” [63.4% (45/71) males versus 42.6% (52/122) females; 
p=0.003]. Additionally, males were more likely to ‘strongly agree’ or ‘agree’ with the 
statement “I do not care if others use substances for cognitive enhancement purposes whilst 
studying,” [67.6% (48/71) males versus 53.3% (65/122) females; p=0.014]. 
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Discussion 
This study has revealed interesting findings about pharmacy students’ use of, and views on, 
CEs. In summary, while one in every two pharmacy students reported using CEs, the most 
commonly used substance was caffeine. Users were equally likely to be first year as final year 
students. There was a slightly greater proportion of female than male users (but this was not 
significant). The main reasons for CE use centred on staying awake and to improve 
concentration. In terms of future pharmacists’ views on safety and ethics of CEs, opinions 
differed depending on whether the CE was a natural substance (i.e. a non-pharmaceutical 
product) or a pharmaceutical (OTC or POM) product.  
 
In terms of gender, other researchers have reported a higher proportion of male than female 
users (Dietz et al., 2013; Kudlow et al., 2013; Singh et al., 2014). However, it must be noted 
that these studies focused more on pharmaceutical CE use rather than CE use in general and 
our work did reveal that male non-users were more likely to consider trying CEs in the future 
than female non-users. Furthermore, unlike other published research (Emanuel et al., 2013; 
Kudlow et al., 2013), non-users were equally likely to be senior as junior students.  
 
Regarding personal use, it was somewhat reassuring to find the majority of users in this current 
study reported taking “soft enhancers” (Maier et al., 2013) rather than POMs or illicit drugs. 
Only 3.2% of students reported using POM CEs which is low compared to other studies across 
the globe involving university students (Mache et al., 2012; Dietz et al., 2013; Singh et al., 
2014; Maier et al., 2015; Bennett and Holloway, 2017; Rathbone, 2017), pharmacy students 
(Bossaer et al., 2013) and medical students (Habibzadeh et al., 2011; Kudlow et al., 2013; 
Emanuel et al., 2013; Micoulaud-Franchi et al., 2014). Moreover, in line with other studies 
(Mache et al., 2012; Micoulaud-Franchi et al., 2014), the majority of respondents who used 
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CEs did so to stay awake and/or enhance concentration during examination preparation or 
studying. Additionally, some students took them for energy and a minority took CEs for stress 
and anxiety relief. There are some concerns that millennial students are unable to withstand 
hard work, social pressure, and are not as resilient as they should be, hence their ‘strawberry 
generation’ classification. They appear to experience more stress and anxiety than previous 
generations (Peterson and Brommelsiek, 2017). Perhaps wider skills and personal 
development, encompassing resilience training, could be valuable.  
 
The majority of respondents had some awareness of safety and risk associated with CE use and 
many considered the University had a responsibility to inform students about CE safety. 
Unsurprisingly, users had fewer concerns than non-users. Respondents distinguished being 
natural and pharmaceutical products and deemed natural substances to be associated with fewer 
side effects. Similarly, other authors have reported perceptions that non-prescription medicines 
are safe and “too weak to cause any real harm,” (Roumie and Griffin, 2004), that 
complementary and alternative medicine (CAM) is a safer alternative to conventional 
pharmaceutical medicine (Hall et al., 2011) and that plant-based products are ‘natural’ and 
therefore  assumed to be safe (Chouakea and Friedman, 2012). Level 4 students had greater 
general awareness about potential side-effects of CEs (and ethical concerns) than Level 1 
students. This is likely to be because they had gained knowledge about medicines, including 
OTC and CAM at the time of data collection whereas the Level 1 students had not. In light of 
these findings, the school should consider explicitly teaching about CEs early in the MPharm 
programme so that all students are fully cognizant of the risks and safety concerns from the 
outset. The British Medical Association has produced guidance on the use of CEs which could 
be useful for MPharm students. It states that there is an uncertain long term risk profile in 
healthy individuals and that high cognitively performing individuals, and those with higher 
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IQs, are unlikely to derive any benefit from pharmaceutical CEs. It does not support the use of 
pharmaceutical CEs and warns that use may be associated with a negative effect on self-control, 
and give rise to overconfidence (British Medical Association, 2015).  
 
Students seemed to have more ethical concerns about the type of CE rather than the concept of 
using CEs and held similar views about use when qualified as when a student. Further research 
should be conducted before conclusions could be reached. Around half of the respondents 
seemed to be broadly accepting of CEs by agreeing that mankind has always used substances 
to enhance performance. Moreover, this cohort of students were ambivalent about future 
pharmacists using CEs being worse than other university students using CEs. Females seemed 
more concerned about fairness than males, and males were less likely than females to consider 
pharmaceutical CE use in academia as being similar to doping in sports. Perhaps this is because 
males are more likely to use doping in sports (Bloodworth et al., 2012) and have a greater 
acceptance of, and likelihood to partake in, risk-taking behaviours (Harris et al., 2006; Hall et 
al., 2013; Hall et al., 2015).  
 
Regarding strengths and weaknesses, this was the first study in the UK to explore first and final 
year pharmacy students’ use and views on CEs, with particular emphasis on natural versus 
pharmaceutical products. It was a timely due to the increasing level of concern over CE activity 
among university students in recent years. Secondly, non-response bias was not overly 
concerning, given the high response rate. The questionnaire could be readily utilised by other 
schools of pharmacy and healthcare disciplines. However, the opinions were captured at one 
point in time, data were self-reported, and the findings are not generalisable. It is plausible that 
pharmacy students did not want to admit to using POMs off-label (or illicit drugs) for cognitive 
enhancement purposes, although having a non-identifiable questionnaire should have 
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minimised this reluctance. Furthermore, the timing of data collection could have influenced 
results. Perhaps if the study had been conducted immediately before the written examinations, 
prevalence of CE use would have been higher. 
 
Conclusions 
Personal use of CEs appears prevalent among these future pharmacists but largely unrelated to 
seniority on the MPharm degree programme or to gender. The substances used did not seem to 
be particularly potent, which is reassuring. Reasons for CE use raise questions about time 
management and organisational skills in these students. Finally, the distinction in views 
between natural substances and pharmaceutical products is noteworthy and worth further 
exploration.  
 
Educational recommendations and future research ideas  
 As some of our findings may be unique to the UK, to the discipline of pharmacy, and 
to our school, we invite readers to contextualise these results to their own degree 
programmes or settings 
 This study provides the impetus for QUB to explicitly address the subject area of CEs 
and to do so at an early stage within the MPharm degree programme. Students should 
be encouraged and supported to develop key skills and knowledge using risk-free 
methods and by having a healthy lifestyle 
 Workshops and debates could investigate the ethics of using non-pharmaceutical and 
pharmaceutical CE in greater depth, given the many possible ways to gain an ‘unfair’ 
advantage over peers within education 
 Since the subject area has relevance to many university students, discussions around 
CE use could become an inter-professional or inter-disciplinary learning opportunity 
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 It would be worthwhile to explore CE use from undergraduate level to when these 
students are healthcare professionals 
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Table I Respondents’ views on CE safety and risk (n=196) 
 
 
 
 
  
 Strongly 
Disagree 
 
 
 
n (%) 
Disagree 
 
 
 
 
n (%) 
Neither 
Agree 
nor 
Disagree 
 
n (%) 
Agree 
 
 
 
 
n (%) 
Strongly 
Agree 
 
 
 
n (%) 
a. Natural substances (such as caffeine) 
used for cognitive enhancement purposes 
are not associated with many side-effects 
4 
(2.0%) 
62 
(31.6%) 
22 
(11.2%) 
80 
(40.8%) 
28 
(14.3%) 
b. Over-the-counter medicines (such as 
ephedrine and pseudoephedrine) used for 
cognitive enhancement purposes are not 
associated with many side-effects 
25 
(12.8%) 
88 
(44.9%) 
57 
(29.1%) 
25 
(12.8%) 
1 
(0.5%) 
c. Prescription-only medicines (such as 
methylphenidate and modafinil) used for 
cognitive enhancement purposes are not 
associated with many side-effects  
46 
(23.5%) 
101 
(51.5%) 
35 
(17.9%) 
13 
(6.6%) 
1 
(0.5%) 
d. Long-term CE use can lead to dependence 3 (1.5%) 
8 
(4.1%) 
17 
(8.7%) 
91 
(46.4%) 
76 
(38.8%) 
e. Using CEs puts students at risk of not 
developing key skills (such as time 
management) 
7 
(3.6%) 
39 
(19.9%) 
56 
(28.6%) 
68 
(34.7%) 
26 
(13.3%) 
f. The University has a responsibility to 
inform students about CEs and associated 
risks 
6 
(3.1%) 
17 
(8.7%) 
48 
(24.5%) 
91 
(46.4%) 
34 
(17.3%) 
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Table II. Respondents’ opinions on the ethics of CE use (n=198 for statements a-h and n=197 
for statements i-k) 
 
 
 Strongly 
Disagree 
 
 
 
n (%) 
Disagree 
 
 
 
 
n (%) 
Neither 
Agree 
nor 
Disagree 
 
n (%) 
Agree 
 
 
 
 
n (%) 
Strongly 
Agree 
 
 
 
n (%) 
a. It is ethical to use a natural substance 
such as caffeine for cognitive 
enhancement purposes  
1 
(0.5%) 
5 
(2.5%) 
41 
(20.7%) 
98 
(49.5%) 
53 
(26.8%) 
b. It is ethical to use over-the-counter 
products such as ephedrine or 
pseudoephedrine off-label for cognitive 
enhancement purposes  
16 
(8.1%) 
70 
(35.4%) 
59 
(29.8%) 
43 
(21.7%) 
10 
(5.1%) 
c. It is ethical to use prescription-only 
medicines such as methylphenidate or 
modafinil off-label for cognitive 
enhancement purposes 
36 
(18.2%) 
72 
(36.4%) 
38 
(19.2%) 
42 
(21.2%) 
10 
(5.1%) 
d. Using natural CEs for the purpose of 
improving assessment grades breaches the 
Code of Conduct for Pharmacy Students  
49 
(24.7%) 
77 
(38.9%) 
46 
(23.2%) 
19 
(9.6%) 
7 
(3.5%) 
e. Using pharmaceutical CEs (over-the-
counter medicines or prescription-only 
medicines) for the purpose of improving 
assessment grades breaches the Code of 
Conduct for Pharmacy Students 
13 
(6.6%) 
43 
(21.7%) 
57 
(28.8%) 
58 
(29.3%) 
26 
(13.1%) 
f. Using natural CEs for the purpose of 
improving patient safety in practice (for 
example, to improve concentration during 
long working hours) breaches the 
pharmacist’s ethical code 
27 
(13.6%) 
82 
(41.4%) 
59 
(29.8%) 
25 
(12.6%) 
5 
(2.5%) 
g. Using pharmaceutical CEs for the 
purpose of improving patient safety in 
practice (for example, to improve 
concentration during long hours) breaches 
the pharmacist’s ethical code 
8 
(4.0%) 
43 
(21.7%) 
57 
(28.8%) 
64 
(32.3%) 
25 
(12.6%) 
h. Using pharmaceutical CEs in academia is 
similar to doping in sports 
16 
(8.1%) 
54 
(27.3%) 
40 
(20.2%) 
66 
(33.3%) 
21 
(10.6%) 
i. Mankind has always used substances to 
enhance performance; pharmaceutical 
CEs are just the most recent form of this 
phenomenon 
2 
(1.0%) 
21 
(10.7%) 
74 
(37.6%) 
82 
(41.6%) 
17 
(8.6%) 
j. I do not care if others use substances for 
cognitive enhancement purposes whilst 
studying 
13 
(6.6%) 
35 
(17.8%) 
33 
(16.8%) 
83 
(42.1%) 
32 
(16.2%) 
k. It is of greater ethical concern if pharmacy 
students use pharmaceutical CEs in 
comparison to other university students 
26 
(13.2%) 
54 
(27.4%) 
58 
(29.4%) 
42 
(21.3%) 
16 
(8.1%) 
28 
 
 
 
Figure 1 Substances used by respondents for cognitive enhancement (n=95; users could 
provide up to 5 substances) 
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Figure 2 Reasons respondents used cognitive enhancers (n=95) 
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